Literature DB >> 16331484

Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis.

Nobuyoshi Kitaichi1, Tadamichi Shimizu, Ayumi Honda, Riichiro Abe, Kazuhiro Ohgami, Kenji Shiratori, Hiroshi Shimizu, Shigeaki Ohno.   

Abstract

BACKGROUND AND AIMS OF THE STUDY: Atopic dermatitis is a chronic inflammatory skin disorder that often involves some ophthalmic features. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that is associated with the generation of cell-mediated immune responses. Although serum MIF levels may be elevated in severe atopic dermatitis, the quantity of MIF in regional ocular fluid remains unknown. We measured MIF levels in tears (lacrimal fluid) of patients with atopic dermatitis. PATIENTS AND METHODS: Tear samples were collected from 16 patients with atopic dermatitis, 10 patients with allergic conjunctivitis, and 15 healthy control subjects. The clinical severity of atopic dermatitis was evaluated according to the Scoring Atopic Dermatitis (SCORAD) index. The index was calculated by summing the following scores: extent criteria, intensity criteria, and subjective symptoms. Macrophage migration inhibitory factor levels were determined by a human MIF enzyme-linked immunosorbent assay. All comparisons were two-tailed, and P values <0.01 were considered as statistically significant.
RESULTS: The mean MIF concentration in lacrimal fluid collected from healthy control subjects was 0.69+/-0.2 ng/ml. The mean tear MIF levels were 17.87+/-6.3 ng/ml in moderate-to-severe atopic dermatitis (SCORAD> or =15, P=0.002), 0.93+/-0.08 ng/ml in mild atopic dermatitis (SCORAD<15), and 2.76+/-0.86 ng/ml in allergic conjunctivitis (P=0.008).
CONCLUSIONS: A proinflammatory cytokine MIF level was elevated in tears as well as serum in cases of severe atopic dermatitis. These results suggest that MIF may play an important role in the induction or enhancement of ophthalmic features related to severe atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16331484     DOI: 10.1007/s00417-005-0168-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis.

Authors:  T Shimizu; J Nishihira; Y Mizue; H Nakamura; R Abe; H Watanabe; A Ohkawara; H Shimizu
Journal:  J Invest Dermatol       Date:  2001-06       Impact factor: 8.551

Review 2.  Atopic dermatitis--messengers, second messengers and cytokines.

Authors:  C A Holden
Journal:  Clin Exp Dermatol       Date:  1993-05       Impact factor: 3.470

3.  Macrophage migration inhibitory factor (MIF) in bronchial asthma.

Authors:  E Yamaguchi; J Nishihira; T Shimizu; T Takahashi; N Kitashiro; N Hizawa; K Kamishima; Y Kawakami
Journal:  Clin Exp Allergy       Date:  2000-09       Impact factor: 5.018

4.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

Authors:  M Bacher; C N Metz; T Calandra; K Mayer; J Chesney; M Lohoff; D Gemsa; T Donnelly; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis.

Authors:  T Shimizu; R Abe; A Ohkawara; J Nishihira
Journal:  J Allergy Clin Immunol       Date:  1999-09       Impact factor: 10.793

6.  Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis.

Authors:  E Uchio; S Y Ono; Z Ikezawa; S Ohno
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

7.  Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis.

Authors:  N Kitaichi; S Kotake; Y Sasamoto; K Namba; A Matsuda; K Ogasawara; K Onoé; H Matsuda; J Nishihira
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-01       Impact factor: 4.799

8.  Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis.

Authors:  T Shimizu; R Abe; A Ohkawara; Y Mizue; J Nishihira
Journal:  Biochem Biophys Res Commun       Date:  1997-11-07       Impact factor: 3.575

9.  Immunophenotyping of the cutaneous infiltrate and of the mononuclear cells in the peripheral blood in patients with atopic dermatitis.

Authors:  R Lever; M Turbitt; A Sanderson; R MacKie
Journal:  J Invest Dermatol       Date:  1987-07       Impact factor: 8.551

Review 10.  Atopic dermatitis: recent trends in pathogenesis and therapy.

Authors:  K D Cooper
Journal:  J Invest Dermatol       Date:  1994-01       Impact factor: 8.551

View more
  3 in total

1.  Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Authors:  Erminia Ridolo; P Kihlgren; I Pellicelli; M C Nizi; F Pucciarini; C Incorvaia
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

2.  Role of macrophage migration inhibitory factor (MIF) in pollen-induced allergic conjunctivitis and pollen dermatitis in mice.

Authors:  Yuka Nagata; Yoko Yoshihisa; Kenji Matsunaga; Mati Ur Rehman; Nobuyoshi Kitaichi; Nobuyuki Kitaichi; Tadamichi Shimizu
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

Review 3.  Potential Biomarkers for Allergic Conjunctival Diseases.

Authors:  Neeta Roy; Shir Levanon; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2020-03       Impact factor: 3.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.